Re-analysis of Selzentry trial confirms efficacy in treatment-naïve HIV patients
This article was originally published in Scrip
Executive Summary
Pfizerhas announced the positive outcome from a re-analysis of a head-to-head Phase III trial pitching its first-in-class CCR5 antagonist, Selzentry (maraviroc) against a standard of care, efavirenz, showing non-inferiority in treatment-naïve patients, with fewer side effects. The findings were presented at the annual meeting of infectious diseases society of America (IDSA) and ICAAC in Washington DC.